Today, 425 million adults live with diabetes, and that number is expected to grow to 629 million by 2045, with the greatest number between the ages of 40 to 59 years old. The global prevalence of diabetes has risen from 4.7 percent in 1980 to 8.5 percent in 2014, with the proportion of type 2 diabetes increasing around the world. On top of those numbers, another whopping 352 million people are at risk of developing type 2 diabetes. According to the 2017 Economic Cost of Diabetes survey sponsored by the American Diabetes Association, the total cost of diabetes was estimated to be $327 billion, a 26 percent increase since 2012. About three-quarters of those costs are associated with direct medical expenditures. Patients with diabetes are expected to pay an average of $9,600 in additional medical costs annually. A diabetes cure could cut out a nice chunk of fat out of those costs, potentially worth $245 billion from the 30 million diabetic Americans alone.


Everyone strays; everyone tries to avoid pain instead of learning from it; everyone has ways of escaping anxiety that aren’t productive. At its best, wellness offers habits and practices around which to build a community that will help you feel whole, or at least distract from the sense of inadequacy that drives people to self-injurious behavior—whether it be substance abuse or gambling or mistreating others or spending three hours a day on Instagram despite knowing it makes us feel bad.
Strengthening muscles eases pressure on the joints and tendons. It also gives you a greater sense of control, which really helps people deal with pain. Stretching to increase your flexibility can also be helpful for pain relief, when done as part of a regular exercise routine. Walking, sitting, and moving with good posture and balance can take pressure off tender muscles and nerves. You may want to consult a physical therapist to find exercises that are right for you.

Poxel (PP:POXEL) is a French pharmaceutical company that recently received $30.1 million in post-IPO equity in 2016. The company has developed an orally active medication called Imeglimin, which targets all three organs and body systems that are affected by diabetes simultaneously: the pancreas, liver, and muscles. The drug is currently undergoing phase 3 clinical work in Japan, and will commence phase 3 trials in the European Union and the United States that will be completed by 2019. The company is also concurrently working on several other pharmaceutical agents in various stages of the development pipeline.

Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes.

×